Shanghai OPM Biosciences Co., Ltd. (SHA:688293)

China flag China · Delayed Price · Currency is CNY
48.64
-0.33 (-0.67%)
Mar 9, 2026, 4:00 PM EDT
22.06%
Market Cap 6.32B
Revenue (ttm) 354.91M
Net Income (ttm) 41.70M
Shares Out 130.04M
EPS (ttm) 0.37
PE Ratio 131.46
Forward PE 50.14
Dividend 0.42 (0.86%)
Ex-Dividend Date Sep 15, 2025
Volume 1,639,516
Average Volume 1,543,575
Open 48.38
Previous Close 48.97
Day's Range 47.67 - 50.47
52-Week Range 31.85 - 67.80
Beta 0.72
RSI 42.96
Earnings Date Apr 23, 2026

About Shanghai OPM Biosciences

Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, and VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream process development, downstream process development, formulation development, and quality control and produ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 64
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688293
Full Company Profile

Financial Performance

In 2025, Shanghai OPM Biosciences's revenue was 354.91 million, an increase of 19.40% compared to the previous year's 297.24 million. Earnings were 41.70 million, an increase of 98.07%.

Financial Statements

News

There is no news available yet.